Learn about ESBL-producing E. coli Urinary Tract Infection (UTI) diagnosis, including clinical documentation and medical coding for Extended-Spectrum Beta-Lactamase E. coli UTI. This resource provides information on ESBL E. coli UTI for healthcare professionals, covering best practices for accurate diagnosis and appropriate treatment strategies. Find key details related to ESBL-producing E. coli in UTI cases.
Also known as
Other specified noninflammatory disorders of female genital tract
Includes other specified noninflammatory disorders of the female genital organs.
Other bacterial agents as the cause of diseases classified elsewhere
Covers E. coli as cause of diseases classified elsewhere.
Diseases of the genitourinary system
Encompasses various urinary tract infections and related conditions.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is UTI confirmed?
Yes
Is E. coli identified?
No
Do not code UTI. Investigate other diagnoses.
When to use each related code
| Description |
|---|
| E. coli UTI resistant to some penicillins and cephalosporins. |
| Uncomplicated UTI caused by E. coli. |
| Complicated UTI due to E. coli. |
Coding lacks specificity if ESBL type (e.g., CTX-M, SHV, TEM) is not documented and coded when available.
Incorrect coding of UTI site (e.g., cystitis, pyelonephritis) can impact severity and reimbursement.
Lack of documentation confirming ESBL production (e.g., lab results) leads to coding and billing errors.
Q: What are the recommended first-line empiric antibiotic treatment options for suspected ESBL-producing E. coli UTI in hospitalized patients with risk factors for resistance?
A: Empiric treatment for suspected ESBL-producing E. coli UTI in hospitalized patients, especially those with risk factors like recent antibiotic use, healthcare-associated infection, or travel to endemic areas, should consider agents with activity against ESBLs. Options may include carbapenems (e.g., ertapenem, imipenem, meropenem) or newer beta-lactam/beta-lactamase inhibitor combinations (e.g., ceftolozane/tazobactam, ceftazidime/avibactam). However, local resistance patterns and patient-specific factors like allergies and renal function must guide antibiotic selection. Definitive therapy should be narrowed based on culture and susceptibility testing. Explore how antibiotic stewardship programs can optimize ESBL UTI management to minimize resistance development.
Q: How do I differentiate between uncomplicated and complicated ESBL E. coli UTI in a clinical setting, and how does this distinction impact treatment decisions?
A: Differentiating between uncomplicated and complicated ESBL E. coli UTI relies on assessing patient-specific factors. Uncomplicated UTIs typically occur in healthy, non-pregnant women without structural or functional urinary tract abnormalities. Complicated UTIs involve factors like male gender, pregnancy, urinary obstruction, indwelling catheters, renal impairment, or diabetes. This distinction is crucial for treatment decisions. Uncomplicated ESBL UTIs might be managed with oral antibiotics like nitrofurantoin (if susceptible) or fosfomycin, while complicated UTIs often require parenteral therapy with carbapenems or other ESBL-active agents for a longer duration. Consider implementing standardized diagnostic and treatment pathways for ESBL UTIs in your practice setting.
Patient presents with symptoms consistent with a urinary tract infection (UTI), including dysuria, frequency, urgency, and suprapubic pain. Urinalysis reveals pyuria and bacteriuria. Urine culture confirms the presence of Extended-Spectrum Beta-Lactamase (ESBL) producing Escherichia coli (E. coli). This ESBL E. coli UTI diagnosis is based on laboratory findings demonstrating resistance to commonly used antibiotics such as ceftriaxone and ceftazidime. Patient's medical history is significant for [insert relevant past medical history, e.g., recent antibiotic use, recurrent UTIs, comorbidities]. Physical examination reveals [insert relevant physical exam findings, e.g., costovertebral angle tenderness, fever]. Differential diagnoses considered included uncomplicated UTI, pyelonephritis, and other bacterial infections. Treatment plan includes [insert specific antibiotic based on susceptibility testing, e.g., carbapenem, fosfomycin] and patient education regarding antibiotic compliance, hydration, and follow-up urine culture. ICD-10 code N39.0 (Urinary tract infection, site not specified) and appropriate resistant organism code will be used for billing and coding purposes. Patient advised to return if symptoms worsen or do not improve within [specified timeframe]. Monitoring for potential complications such as urosepsis and acute kidney injury will be conducted.